- Sysmex Kimdir?
- Kalite ve Süreklilik
- Haberler ve Etkinlikler
- Akış Sitometrisi
- Hijyen Ürünleri
- Kalite Kontrol ve Online Hizmetler
- Belge Merkezi ve Yüklemeler
- Bilgi Merkezi
- Klinik ve Laboratuvar
- Neden Sysmex’te çalışmalısınız?
Select your local website
OSNA in gastric cancer
Informed decisions for therapy depend on accurate staging
- Precise lymph node analysis providing more accurate staging
- Easier therapy decisions thanks to reliable diagnostic information
- CE-marked for gastric, colon and breast cancer
- Highly productive analyses from multi-cancer application
Using the sentinel concept often reduces the need for lymphadenectomy. This is true for several different types of cancer, including gastric cancer. In early gastric cancer, lymph node metastasis occurs in some 10-16% of cases1, so patients could benefit from a less invasive surgery. The intraoperative OSNA result can support your immediate decision on further lymph node dissection.
OSNA – benefit from intelligent diagnostics
- Enables immediate and fully-informed decisions during surgical procedures
- Confidence not to overlook metastases by analysing the entire lymph node
- Standardised and observer-independent
OSNA for GC in clinical studies
OSNA provides a diagnostic ability equivalent to the postoperative histological examination with a concordance rate between the two methods of 0.942 (2).
OSNA was more sensitive in detecting metastases compared to conventional histology, resulting in an upstaging rate of 20%. Some 1,000 lymph nodes were examined and the nodal status could be predicted in all cases, another study concluded (3).
Its accuracy and fast availability of results makes OSNA suitable for early-stage sentinel lymph node analysis and reliable intraoperative decisions.
(1) Croner RS, Geppert C-I, Bader FG et al. (2014): Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study. Br. J. Cancer 110: 2544-2550.
(2) Yamamoto H, Tomita N, Inomata M et al. (2015): OSNA-Assisted Molecular Staging in Colorectal Cancer: A Prospective Multicenter Trial in Japan. Ann. Surg. Oncol. 1-6.
(3) Matsuura N et al. (2017): Clinical impact of molecular positive lymph node status in colorectal cancer. Ann. of Oncol. 28 (suppl. 5): v158 – v208.
(4) Kumagai et al. (2014): Multicentre study evaluating the clinical performance of the OSNA assay for the molecular detection of lymph node metastases in gastric cancer patients. Gastric Cancer. 17(2):273-80
(5) B. Martin, N. Balagiannis, M. Anthuber, B. Kriening, B. Märkl (2018): OSNA (One-step nucleic acid amplification) Lymphknotenevaluation in Kombination mit ex-vivo Sentinellymphknotenmarkierung bei Magenkarzinomen – Interimsergebnisse einer prospektiven Studie. Presented at the DGP (Deutschen Gesellschaft für Pathologie) congress in Berlin, May 2018.
(6) Daisaku Morita et al. (2007): Analysis of sentinel node involvement in gastric cancer. Clin. Gastroent. and Hepato. 5:1046-1052.